SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
(Amendment #1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report: August 8, 2003 (Date of the Earliest Event Reported: August 5, 2003)
ICN Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 1-11397 33-0628076
-------- ------- ----------
(State or other jurisdiction of (Commission (I.R.S. Employer
incorporation or organization) file number) Identification No.)
3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip code)
(714) 545-0100
(Registrant's telephone
number, including area code)
The Company is amending its Current Report on Form 8-K filed on August 5, 2003,
as follows:
Item 7. Financial Statements and Exhibits
The Company is furnishing additional financial information as Exhibit 99.2 to
the Current Report.
(c) Exhibits
Exhibit No. Description
99.2 Additional Financial Data
Item 9. Regulation FD Disclosure
The Company is furnishing additional financial information in Exhibit 99.2.
Item 12. Results of Operations and Financial Condition
On August 5, 2003, the Company furnished certain information in a press release
attached as Exhibit 99.1 to a Current Report on Form 8-K. The information was
furnished pursuant to Item 12 of Form 8-K, but appeared under the caption for
"Item 9. Regulation FD Disclosure." The information should have been under the
caption for "Item 12. Results of Operations and Financial Condition."
Table 2 attached to the press release included certain information regarding the
Company's income from continuing operations (and diluted earnings per share from
continuing operations) for the three and six months ended June 30, 2002,
excluding certain non-recurring items specifically described in such table. The
Company believes that excluding these non-recurring items from income from
continuing operations provides a more meaningful basis for comparing the
Company's results from those periods to the comparable periods in 2003, which
did not include those items.
Table 4 attached to the press release also included certain information
regarding the impact of foreign currency fluctuations on specialty
pharmaceutical revenues and operating income for the three and six months ended
June 30, 2003. The Company routinely evaluates the impact that currency
fluctuations have on its revenues and operating income because the Company
believes it provides a more meaningful basis for comparing actual local currency
revenue performance between different periods.
The Company is also furnishing additional financial information in Exhibit 99.2.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, ICN
Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: August 8, 2003 ICN PHARMACEUTICALS, INC.
/s/ Robert W. O'Leary
Chairman and Chief Executive Officer
Exhibit 99.2
Additional Financial Data
Consolidated Condensed Statement of Gross Profit on Product Sales for the three and six months ended
June 30, 2003 and 2002: (in thousands)
Three Months Ended Six Months Ended
June 30, June 30,
---------------------------- ----------------------------
2003 2002 2003 2002
---------------------------- ----------------------------
North America $ 20,106 $ 16,023 $ 30,305 $ 52,185
Latin America 24,014 24,055 43,245 45,224
Europe 32,862 30,419 66,456 58,663
AAA 6,252 6,959 12,494 13,153
------------- ------------- ------------- -------------
Total pharmaceuticals $ 83,235 $ 77,456 $ 152,499 $ 169,225
============= ============= ============= =============